VistaGen Therapeutics (VTGN) Stock Price, News & Analysis

Company Overview

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with an emphasis on anxiety, depression and related conditions. The company is headquartered in South San Francisco, California, and conducts its development activities primarily in the United States.

VistaGen’s lead product candidate is fasedienol, also known as PH94B, an investigational neuroactive nasal spray being developed for the treatment of social anxiety disorder and other anxiety-related conditions. The company’s approach is intended to provide rapid, non-systemic treatment through nasal administration. Fasedienol remains an investigational product and has not been approved for commercial sale.

The company also maintains a broader neuroscience pipeline that has included other intranasal drug candidates, including PH80, as it evaluates potential treatments for psychiatric and neurological conditions. VistaGen’s programs are subject to clinical testing and regulatory review, and their development status may change as additional data become available. Shawn Singh serves as the company’s chief executive officer.

Key Stats

• Today's Range: $0.20 to $0.22
• 50-Day Range: $0.21 to $0.37
• 52-Week Range: $0.20 to $5.14
• Volume: 558,431 shs
• Average Volume: 4.95 million shs
• Market Capitalization: $8.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $0.95
• Consensus Rating: Reduce

VistaGen Therapeutics Stock Analysis - MarketRank™

VistaGen Therapeutics scored higher than 47% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Reduce

Consensus Rating

VistaGen Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

VistaGen Therapeutics has a consensus price target of $0.95, representing about 375.0% upside from its current price of $0.20.

Amount of Analyst Coverage

VistaGen Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for VistaGen Therapeutics are expected to decrease in the coming year, from ($1.45) to ($1.54) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of VistaGen Therapeutics is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of VistaGen Therapeutics is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

VistaGen Therapeutics has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.71% of the float of VistaGen Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

VistaGen Therapeutics has a short interest ratio ("days to cover") of 0.07, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in VistaGen Therapeutics has recently increased by 38.56%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

VistaGen Therapeutics does not currently pay a dividend.

Dividend Growth

VistaGen Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: N/A

News Sentiment

VistaGen Therapeutics has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

Search Interest

6 people have searched for VTGN on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

1 people have added VistaGen Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, VistaGen Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.93% of the stock of VistaGen Therapeutics is held by insiders.

Percentage Held by Institutions

78.39% of the stock of VistaGen Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VTGN
• CIK: 1411685
• Web: www.vistagen.com
• Phone: (650) 577-3600
• Fax: 888-482-2602
• Employees: 41
• Year Founded: 1998

Price Target and Rating

• Average Price Target for VistaGen Therapeutics: $0.95
• High Price Target: $1.00
• Low Price Target: $0.90
• Potential Upside/Downside: +375.0%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.66)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$69.68 million
• Net Margins: -2,702.64%
• Pretax Margin: -2,702.36%
• Return on Equity: -152.59%
• Return on Assets: -117.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.07
• Quick Ratio: 3.07

Sales & Book Value

• Annual Sales: $1.27 million
• Price / Sales: 6.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.90 per share
• Price / Book: 0.22

Miscellaneous

• Outstanding Shares: 44,380,000
• Free Float: 43,077,000
• Market Cap: $8.88 million
• Optionable: Optionable
• Beta: 0.33